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Chronic mucocutaneous candidiasis (CMC) is frequently associated with T cell immunodefi-
ciencies. Specifically, the proinflammatory IL-17A–producing Th17 subset is implicated in 
protection against fungi at epithelial surfaces. In autoimmune polyendocrinopathy candi-
diasis ectodermal dystrophy (APECED, or autoimmune polyendocrine syndrome 1), CMC is 
often the first sign, but the underlying immunodeficiency is a long-standing puzzle. In 
contrast, the subsequent endocrine features are clearly autoimmune, resulting from defects 
in thymic self-tolerance induction caused by mutations in the autoimmune regulator 
(AIRE). We report severely reduced IL-17F and IL-22 responses to both Candida albicans 
antigens and polyclonal stimulation in APECED patients with CMC. Surprisingly, these 
reductions are strongly associated with neutralizing autoantibodies to IL-17F and IL-22, 
whereas responses were normal and autoantibodies infrequent in APECED patients without 
CMC. Our multicenter survey revealed neutralizing autoantibodies against IL-17A (41%), 
IL-17F (75%), and/ or IL-22 (91%) in >150 APECED patients, especially those with CMC. 
We independently found autoantibodies against these Th17-produced cytokines in rare 
thymoma patients with CMC. The autoantibodies preceded the CMC in all informative 
cases. We conclude that IL-22 and IL-17F are key natural defenders against CMC and that 
the immunodeficiency underlying CMC in both patient groups has an autoimmune basis.
© 2010 Kisand et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/). K. Kisand and A.S. Bøe Wolff contributed equally to this paper.
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explain the susceptibility to it (Lindh et al., 2008; Pöntynen 
et al., 2008; Ryan et al., 2008).
We have recently reported high-titer neutralizing auto-
antibodies against all 12 IFN- subtypes, and especially IFN-, 
in almost all APECED patients, whatever their exact AIRE 
mutation or clinical picture (Meager et al., 2006; Meloni et al.,   
2008). These are rarely seen in other disorders, although 
patients with thymomas uniquely show intriguing parallels; 
65% have anti-IFN autoantibodies at diagnosis (Meager 
et al., 1997) and rare cases develop CMC.
In this paper, we describe decreased IL-22 and IL-17F 
responses in patients with APECED or thymomas, which 
correlate  with  both  CMC  and  neutralizing  autoantibodies 
against these cytokines. We therefore conclude that even the 
CMC can have an autoimmune basis.
RESULTS AND DISCUSSION
Th17 responsiveness of APECED patient PBMCs
Th17 cells have been implicated in protection against C. albi-
cans infection (Ma et al., 2008; Conti et al., 2009), so we first 
investigated their role in APECED. We compared responses 
of PBMCs from patients with and without CMC (Table I) 
and age-matched healthy controls to C. albicans antigens or 
staphylococcal enterotoxin B (SEB) as polyclonal stimulus.   
Production  of  IL-17A  was  not  significantly  altered  in  the 
patients overall, whether measured by ELISA in culture 
supernatants  or  by  quantitative  RT-PCR  on  cell  mRNA 
(Fig. 1 A and Fig. S1). In contrast, IL-17F and especially IL-22 
responses were significantly and consistently reduced in the 
patients with CMC but unaltered in the rare cases without 
it (Fig. 1 A). These reductions were seen at both time points 
tested and in levels of both protein and mRNA (Fig. 1 A 
and Fig. S1). Among other Th17-associated cytokines, IL-21 
showed marginal increases in CMC patients, whereas IL-26 
was unchanged (Fig. S1).
Notably, the reductions in IL-17F and IL-22 responses 
were not C. albicans antigen specific but were also seen after 
SEB stimulation. This could reflect loss of cytokine-producing 
cells, which we checked by intracellular cytokine staining. 
Indeed, frequencies of IL-22–secreting Th cells were very 
low in APECED patients with CMC, whereas those without 
CMC showed no differences from healthy controls (Fig. 1 B). 
Percentages of IL-17A–secreting cells were variable though 
not  significantly  changed  overall  (Fig.  1  B).  Collectively, 
these results show significant decreases in IL-17F and IL-22 
production and an almost complete lack of IL-22–producing 
cells in APECED patients with CMC. Thus, they imply that 
protection against CMC in humans depends more on IL-22 
and IL-17F than on the more extensively studied IL-17A.
Autoantibodies against Th17-associated cytokines
We next sought to understand the basis for these cytokine 
secretion defects. Recalling the high prevalences and titers of 
neutralizing autoantibodies against type I IFNs in APECED 
(Meager et al., 2006; Meloni et al., 2008), we hypothesized 
that analogous autoimmunity against Th-17–related cells and 
Candida albicans can be both a commensal microorganism and 
a pathogen in humans, infecting epithelial sites or internally. 
Chronic  mucocutaneous  candidiasis  (CMC),  i.e.,  persistent 
or recurrent infections of nail beds, skin, and mucosal sur-
faces, occurs in primary or secondary immunodeficiencies, 
including HIV. Protection is thought to be T cell mediated, 
particularly by IL-17–producing Th17 cells at epithelial sur-
faces (LeibundGut-Landmann et al., 2007; Curtis and Way, 
2009). Indeed, the natural Th17 memory repertoire includes 
many C. albicans–specific Th17 cells (Acosta-Rodriguez et al., 
2007). CMC and impaired Th17 production are also promi-
nent in the autosomal dominant hyper-IgE syndrome caused   
by STAT3 mutations (de Beaucoudrey et al., 2008; Ma et al.,   
2008; Milner et al., 2008) and in patients with defective 
CARD9 (Glocker et al., 2009) or dectin-1 (Ferwerda et al.,   
2009).  In  addition,  heterogeneous  patients  with  isolated 
CMC show reduced production of Th17-associated cytokines   
(Eyerich et al., 2008).
In  addition  to  protecting  against  infections, Th17  cells 
have been implicated in several autoimmune diseases (Korn 
et al., 2009). Th17 cells characteristically express the transcrip-
tion factor RORC (retinoic acid orphan receptor t; Ivanov   
et al., 2006), IL-23R (IL-23 receptor), CCR6 (CC chemokine 
receptor 6), and CCR4 (Acosta-Rodriguez et al., 2007), which 
facilitate their migration to epithelial areas. By producing IL-
17A and IL-17F (as homo- or heterodimers), as well as IL-22, 
IL-21, and IL-26, they trigger the subsequent production of 
neutrophil-recruiting and -activating cytokines and chemo-
kines, proinflammatory cytokines, and antimicrobial peptides 
in many cell types (Liang et al., 2006; Wolk et al., 2006; Fouser 
et al., 2008; Korn et al., 2009). Recently, a skin-homing IL-
22+/IL-17A subset of Th cells has been described (Duhen   
et al., 2009; Trifari et al., 2009). IL-22 has important protective 
functions at epithelial surfaces, critically regulating antimicro-
bial genes and maintaining barrier integrity (Wolk et al., 2006; 
Aujla and Kolls, 2009).
Usually, CMC is the earliest and most common sign of 
autoimmune  polyendocrinopathy  candidiasis  ectodermal 
dystrophy (APECED; Husebye et al., 2009). This autosomal 
recessive syndrome results from defects in the autoimmune 
regulator (AIRE) gene (Nagamine et al., 1997), in which 60 
different  mutations  are  now  known. The  commonest  are 
p.R257X in exon 6 and a 13-bp deletion in exon 8. Many 
point substitutions, small insertions, deletions, and splice-site 
mutations have also been reported. The AIRE protein is prin-
cipally expressed in medullary thymic epithelial cells where it 
normally prevents autoimmunity by regulating expression of 
peripheral tissue-specific antigens that induce self-tolerance 
in developing T cells (Anderson et al., 2002; Liston et al., 
2003; Peterson et al., 2008; Mathis and Benoist, 2009). The 
known defects in central tolerance induction in this highly 
variable  syndrome  contrast  strikingly  with  the  consistent 
and selective C. albicans susceptibility. Several groups have 
noted  modest  and  sometimes  contradictory  abnormalities 
in peripheral dendritic cell function in APECED patients. 
These did not correlate with their CMC and so still cannot JEM VOL. 207, February 15, 2010  301
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(Fig. 2 F). These included many with only weak or undetectable 
autoantibodies against IL-17s. We therefore use neutralizing 
titers against IL-22 for optimal quantification and sensitivity 
in most subsequent analyses. Sera from unaffected heterozy-
gous relatives of APECED patients and healthy controls were 
negative in all three neutralizing assays (Fig. 2 F, shown against 
IL-22).  Further  screening  revealed  no  additional  positives 
against IL-17A/F heterodimer and also very few low positives 
(by ELISA) against IL-17B, IL-17C, or IL-17D (unpublished 
data), which are produced in other tissues and not by Th17 
cells. We also noted only occasional or weakly binding auto-
antibodies against IL-6, IL-9, IL-12, IL-21, IL-23, IL-26, IL-
29, or RANTES and none against IL-1/, IL-2, IL-4, IL-8, 
IL-10, IL-18, TGF-1, or TNF (unpublished data).
We next assessed the disease specificity of the anti–IL-17 
and –IL-22 autoantibodies. Their levels proved to be minimal 
or negative in other patients with just one of the APECED 
triad,  i.e.,  CMC  without  AIRE  mutations,  isolated  hypo-
parathyroidism (HP), or Addison’s disease (AD), autoimmune 
polyendocrine syndrome II, and also in diseases where Th17 
cells or type I IFNs are implicated, such as Sjögren’s syndrome, 
psoriasis,  systemic  lupus  erythematosus,  and  rheumatoid 
arthritis (Fig. 2, A–C and F). The only clear exceptions were 
in thymoma patients (see next section).
cytokines is one likely mechanism underlying these defects 
and predisposing to CMC. Remarkably, we detected serum   
autoantibodies against IL-17A, IL-17F, and/or IL-22 in the 
great majority of the 162 patients, with diverse AIRE muta-
tions. In ELISAs, we found binding IgG autoantibodies to IL-
17A in 67 of 162 (41%), to IL-17F in 121 of 162 (75%), and 
to IL-22 in 86 of 99 (87%) APECED patients (Fig. 2, A–C). 
In sharp contrast, their levels were low or undetectable in 
healthy  subjects  and  unaffected  relatives  heterozygous  for 
AIRE mutations. The few patients negative for IL-22 auto-
antibodies also tested negative against IL-17F and IL-17A 
(with a single exception). To test whether these responses 
were primarily mucosal, we checked their Ig isotypes. In fact, 
they proved to be predominantly IgG. Binding signals for 
IgA appeared weaker for every sample tested (Fig. S2 A).
Importantly, both IL-17A and IL-17F were clearly neu-
tralized in functional assays by most of the sera with binding 
values over three (Fig. 2, D and E). The corresponding bind-
ing and neutralizing titers correlated very well (r = 0.90 and 
r = 0.84, P < 0.001; Fig. S2 B). Interestingly, against IL-22, 
binding signals rarely reached saturation (Fig. 2 C), suggest-
ing a relatively low gain in this particular ELISA (see Fig. S2).   
In sharp contrast, 136 of 150 (91%) patients tested positive   
in IL-22 neutralization assays, nearly all with titers >1,000   
Table I.  APECED patients whose PBMCs were tested for cytokine responses
Patient AIRE mutation Age CMC FACS 
sample
Sample at 
72 h
Neutralizing antibody titer against: Binding antibodies against: a
IFN- IL-17A IL-17F IL-22 IL-17A IL-17F IL-22
yr
A c.[769C>T] + [769C>T]b 29 Yes No No 20,000 <32 38 9,000 0.12 3.11 0.17
Bc c.[21_43dup23]  
+ [21_43dup23]
10 Yes Yes Yes >51,200 250,000 75 9,000 3.85 2.43 0.55
C c.[769C>T] + [769C>T] 17 Yes Yes Yes >51,200 <32 56 5,500 0.07 1.30 0.28
D c.[1064-1068dupCCCGG] 
+ [1064-1068dupCCCGG]
18 Yes Yes Yes >51,200 <32 1,250 >525,000 0.83 3.64 1.81
E c.[769C>T] + [769C>T] 18 Yes No No >51,200 <32 350 160,000 0.70 3.52 1.01
F c.[769C>T] + [769C>T] 23 Yes No Yes 20,000 15,000 1,300 95,000 3.90 3.90 0.79
G c.[769C>T] + [769C>T] 60 Yes Yes Yes 12,800 <32 300 13,000 0.39 3.89 0.64
H c.[769C>T]  
+ [967_979del13]
20 Yes No Yes 100,000 <32 5,500 4,500 2.98 3.90 0.25
I c.[967_979del13]  
+ [1163_1164insA]
24 Yes No Yes 256,000 nd 9,200 3,300 0.09 3.90 0.56
J c.[879 + 1G>A]  
+ [879 + 1G>A]
48 No Yes No 30,000 <32 <32 <32 0.30 0.29 0.18
Kc c.[967_979del13]  
+ [967_979del13]
21 No Yes Yes >51,200 <32 <32 <32 0.17 0.40 0.24
L c.[769C>T] + [c.274C>T] 55 No No Yes 12,000 <32 <32 <32 0.04 0.03 0.16
M c.[967_979del13]  
+ [c.274C>T]
29 No Yes Yes 200,000 <32 <32 930 0 0.03 0.21
Nd c. [682T>G] + [=] 40 No Yes Yes 9,000 <32 <32 <32 0.01 0.16 ND
aPositive is a value >0.4 for anti–IL-17A and anti–IL-17F and >0.2 for anti–IL-22.
bThe mutation c.769C>T causes truncated AIRE protein p.R257X.
cPBMCs from patients B and K were tested repeatedly 6 mo apart. The results (unpublished data) were similar to the first stimulation.
dDominant mutation p.G228W.302 Candidiasis and autoimmunity | Kisand et al.
autoantibody  titers  may  then  have  declined  before  sam-
pling. Furthermore, autoantibody levels appeared to be lower 
against IL-17F in 11 patients with unusually late-onset CMC 
(at 18–30 yr of age) than in 68 patients with childhood-onset 
CMC sampled as adults (P = 0.02).
Very rarely, thymoma patients develop CMC, whose 
pathogenesis remains unknown (Asherson and Webster, 1980). 
Strikingly, 2 of the 35 patients screened showed high binding   
and neutralizing titers against both IL-17A and IL-22 (Fig. 2, A   
and F; and Table S2). They were the only patients with doc-
umented CMC (cases T1 and T2). We also found similar 
autoantibodies in several other thymoma patients selected 
because of known C. albicans infections (Table S2).
Notably, the autoantibody titers were already high before 
CMC onset in the informative sera from four patients with 
APECED (Fig. S2 C, left) and one with thymoma (Fig. S2 C, 
right). Their titers showed no clear increases after CMC onset, 
suggesting that they are not solely an effect of candidia-
sis. Possibly, some of the rare autoantibody-positive patients 
without CMC in our analysis may develop it later. If so, the 
73 patients were studied serially. In nearly all the positives, 
autoantibodies against IL-17 and/or IL-22 were already pres-
ent (or maximal) in the earliest samples, and, in two cases,   
even before the anti–type I IFN autoantibodies. However, 
titers against these Th17 cytokines were frequently lower two 
to three decades later, whereas those against the IFNs appear 
more stable (Meager et al., 2006; Meloni et al., 2008). Indeed, 
the anti–IL-22 and –IL-17F antibodies correlated negatively 
with age-at sampling (r = 0.44, P < 0.001; r = 0.25,   
P = 0.002).
Clinical correlates of the autoantibodies
We next checked for associations of these autoantibodies with 
the patients’ CMC. These proved to be highly significant for 
anti–IL-17F and –IL-22; the titers were higher (Fig. 3 A) 
and they occurred more frequently (Table S1) in APECED 
patients with CMC than without it. This association was not   
absolute; 8 of the 15 cases without anti–IL-22 autoantibodies   
nonetheless had CMC. However, in at least 3 of these 8, the 
candidiasis  had  never  recurred  after  early  childhood,  and 
Figure 1.  Decreased IL-17F and IL-22 responses associate with CMC in APECED patients. (A) Secretion of IL-17A, IL-17F, and IL-22 by PBMCs 
from APECED patients without (CMC) or with (CMC+) CMC and age-matched controls (Ctrl, n = 14 at 72-h time points) after stimulation with heat-
killed C. albicans hyphae or SEB for 72 h was measured by ELISA. The patients are detailed in Table I. (B) SEB-stimulated PBMCs were stained intracellu-
larly for IL-17A and IL-22 and FACS analyzed. Horizontal bars represent median values. A Kruskal-Wallis test was used to compare the group medians. 
This figure represents three independent experiments. Each symbol corresponds to a value obtained from an individual.JEM VOL. 207, February 15, 2010  303
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addition, the autoantibodies did not correlate clearly with any 
other APECED manifestation.
Intriguingly, we noted that certain mutations associated 
more strongly with both the autoantibodies and CMC. At 
one  extreme,  every  p.R257X  homozygote  (61  from  Fin-
land, 5 from Slovenia, and 2 from Norway) had CMC and 
was positive against IL-22, and 64 were also positive against 
autoantibodies against IL-17 and IL-22 might prove to be use-
ful predictors of CMC susceptibility that could be assessed in 
prospective serial studies in AIRE mutant siblings of APECED 
probands (or thymoma patients). These autoantibodies were 
also evident in nearly every informative sample taken before 
onset of HP (n = 2) or AD (n = 16) and, thus, seem not to 
be effects either of these components or of their treatments. In 
Figure 2.  Disease-specificity of autoantibodies to IL-17A, IL-17F, and/ or IL-22. (A–C) Autoantibodies binding human IL-17A, IL-17F, and/ or  
IL-22 in sera from APECED or thymoma patients and disease or healthy controls tested by ELISA. (D and E) Comparisons of neutralizing and binding activ-
ity of anti–IL-17A and anti–IL-17F. (F) Because ELISA underestimates antibodies against IL-22, we used neutralizing assays for systematic comparisons.  
12 sera were exhausted before exact titration of anti-IL-22 could be done. Red and black bars indicate group medians. SLE, systemic lupus erythematosus; 
RA, rheumatoid arthritis. Open circles represent patients T1 and T2 (Fig. 3 C and Table S2).304 Candidiasis and autoimmunity | Kisand et al.
Figure 3.  Autoimmunity to Th17-related cytokines is associated with CMC and cytokine productivity in vitro. (A) Associations between CMC 
and anti-cytokine autoantibodies in APECED patients. Red bars indicate group medians. (B) Representative FACS plots for intracellular IL-22 and IL-17A in 
a healthy subject (left) or in APECED patients with CMC and antibodies against IL-22 alone (middle) or against both IL-17A and IL-22 (right) after 6 h of 
SEB stimulation. (C) Production of IL-17A, IL-17F, and IL-22 by C. albicans– and SEB-stimulated (72 h) PBMCs from five random myasthenia gravis/thymoma 
patients was measured with ELISA. Patients T1 (X) and T2 (O) proved to be the only two with CMC. Median values for healthy controls are indicated 
with gray bars. (D) The concentration of secreted IL-17F (left) and IL-22 (right) after stimulating APECED patients’ PBMCs with SEB (for 72 and 18 h, re-
spectively) correlates negatively with the respective neutralizing antibody titer. (E) Normal naive T cells were differentiated to Th17 cells with IL-1, IL-6, 
IL-23, and IL-21 in the presence of sera (1:10) from either controls or APECED patients with antibodies to IL-22, IL-17F, and/or IL-17A. The IL-22– and IL-
17A–producing cells were enumerated by flow cytometry. Data are representative of three independent experiments. Horizontal bars show median values.JEM VOL. 207, February 15, 2010  305
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Ma et al., 2008; Milner et al., 2008; Conti et al., 2009; Curtis 
and Way, 2009).
We now show high-titer anti-Th17 cytokine autoanti-
bodies and decreased Th17-related responses in APECED 
and thymoma patients with CMC. We therefore propose 
that their CMC susceptibility is primarily a result of ante-
cedent immune attack on IL-22–expressing cells and on the 
IL-17A, IL-17F, and IL-22 that they produce. Because IL-22 
especially protects epithelial surfaces (Liang et al., 2006; Aujla 
and Kolls, 2009) and IL-22+/IL17 cells show skin-homing 
properties (Duhen et al., 2009; Trifari et al., 2009), our find-
ings may help to explain the mucocutaneous rather than sys-
temic focus of the candidiasis in both patient groups. The 
apparent specificity for C. albicans remains unexplained but 
probably highlights the reserve capacity in human immune 
defenses. Indeed, similarly restricted susceptibilities to certain 
organisms, such as atypical mycobacteria, are seen in patients 
genetically deficient in multifaceted pathways (Bustamante 
et al., 2008) such as those involving IL-12 and IFN-. Even 
more importantly, this susceptibility is likewise phenocopied 
in patients with autoantibodies against IFN- (Notarangelo 
and Casanova, 2009). In contrast, the neutralizing autoan-
tibodies against type I IFNs in APECED seem neither to 
predispose to viral infections (Meager et al., 2006) nor to 
affect type I IFN production by APECED DCs (Kisand et al., 
2008). However, they might conceivably bias toward condi-
tions favorable for C. albicans and so might the anti–IL-12/23 
autoantibodies in thymoma patients (Table S2).
The  striking  serological  and  cellular  parallels  between 
APECED and thymoma patients seem to implicate shared 
thymic aberrations in autoimmunization against cytokines. 
Tissue-specific  autoimmunity  in  APECED  is  thought  to 
develop  to  antigens  that  are  not  expressed  in  the AIRE-
deficient thymus (Anderson et al., 2002; Liston et al., 2003; 
Mathis and Benoist, 2009). In contrast, type I IFNs and Th17-
related cytokines are made in the thymus by several cells of 
hematopoietic  origin  (Meager  et  al.,  2006;  Cooper  et  al., 
2009; Marks et al., 2009), and their expression levels are most 
likely not directly regulated by AIRE. This suggests a different 
mechanism of autoimmunization. We recently proposed that 
thymic microenvironments, which are rendered dangerous by 
the tumor or by the absence of AIRE, can be responsible for 
breakdown of tolerance to cytokines (Meager et al., 2008).
Finally, our findings have several implications for thera-
pies. Immunosuppressive treatments should at least be con-
sidered for the CMC in APECED, as it now appears to have 
an autoimmune basis analogous to the bone marrow aplasias 
in thymoma patients, for which these treatments are rou-
tine. They have not been tested systematically in APECED, 
although cyclosporin A has been shown to reverse pancre-
atic insufficiency, keratitis, and alopecia (Ward et al., 1999). 
Moreover,  regression  of  disease  manifestations,  including 
candidiasis and autoantibody levels, was observed in a patient 
receiving  tacrolimus,  mycophenolate  mofetil,  and  predni-
sone (Ulinski et al., 2006). Next, our data argue that IL-22 is 
more protective than IL-17A against CMC, which persisted 
IL-17F. In contrast, among 20 c.967_979del13 homozygous 
patients (13 from Norway, 6 from USA, and 1 from Paki-
stan), 7 were negative against IL-17F and 1 against IL-22, and 
these also included the 7 without CMC. Moreover, autoan-
tibodies and CMC were both rare in a unique family with 
a dominant-negative p.G228W substitution (Cetani et al., 
2001) that cosegregates mainly with autoimmune thyroiditis 
and autoantibodies to type I IFNs (Meloni et al., 2008). Only 
two of these six relatives have had CMC (and only one with 
the full APECED triad). All six were negative against both 
IL-22 and IL-17A in single bleeds, and just one of the two 
with CMC was weakly positive against IL-17F. These appar-
ent associations between AIRE genotype and autoantibodies 
or CMC require confirmation with larger patient numbers to 
exclude possible confounding factors, whether genetic, envi-
ronmental, or clinical (e.g., CMC onset age or duration).
Possible implications of anti-cytokine autoantibodies
We immediately noticed that neutralizing titers were high 
against IL-17F and IL-22 in all the CMC+ APECED patients 
whose  PBMC  had  shown  reduced  productivity  of  either 
cytokine in Fig. 1 (Table I). In contrast, they were weak 
or negative against IL-22, IL-17F, and IL-17A in the five 
CMC patients with IL-17F and IL-22 responses in the nor-
mal range (Table I). Notably, although anti–IL-17A autoanti-
bodies were less prevalent overall, the one patient (Table I, B)   
with very high titers against it had undetectable IL-17A 
responses, lacking both IL-22– and IL-17A–producing cells 
(Fig. 3 B, right). Indeed, we noted strong negative correla-
tions between the amounts of secreted IL-17F and IL-22 and 
the corresponding neutralizing antibody titers in APECED 
(Fig. 3 D). Moreover, PBMC from the two thymoma patients 
with CMC and autoantibodies to all three cytokines likewise 
showed the lowest cytokine productivity (Fig. 3 C).
Brucklacher-Waldert et al., (2009) have recently detected 
IL-17A and IL-17F on the surface of activated Th17 cells. We 
therefore tested for effects of the autoantibodies themselves 
on Th17 cell development. We cultured naive CD4+ T cells 
from healthy donors in Th17-driving conditions in the pres-
ence of control sera or APECED sera containing high titers of 
anti-cytokine autoantibodies. Interestingly, we saw no effect 
on Th17 polarization (Fig. 3 E), arguing against direct inhibi-
tion by these antibodies in vitro. However, we cannot rule 
out opsonization or antibody-dependent cellular cytotoxicity 
reactions in vivo. Additional cell-mediated attack on Th17 
subsets might also contribute to the deficient IL-17F and IL-
22 production (Fig. 1 and Fig. 3 C), possibly even in patients 
without the antibodies.
Conclusions
Clinically, APECED is highly variable, including in the CMC 
onset age (even in p.R257X homozygotes), so there must 
be multiple predisposing factors, whether genetic, immuno-
logical, or environmental. Nevertheless, Th17 cells that pro-
duce IL-17 and IL-22 are crucial in protection against oral 
or mucocutaneous candidiasis (de Beaucoudrey et al., 2008; 306 Candidiasis and autoimmunity | Kisand et al.
(Applied Biosystems) and qPCR SYBR Green Core kit (Eurogentec). All 
samples were normalized to expression of -actin.
ELISAs. Wells  were  coated  with  IL-17A,  IL-17F,  IL-17A/F,  and  IL-22 
(R&D Systems) at 2 µg of protein/ml in PBS, pH 7.0, and blocked with 3% 
HSA. Sera were added for 2 h at 22°C before washing and development 
with anti–human IgG or IgA–alkaline phosphatase conjugate (Sigma-Aldrich). 
P-nitrophenyl phosphate substrate, and then 3 M NaOH, were added, and 
the absorbances were read at 405 nm. Any values >2 SD above the mean of 
120 healthy controls were considered positive.
Cell-based IL-17 and IL-22 neutralization assays. HFB4 human fore-
skin  fibroblast  cells  (Schering-Plough  Corporation)  were  maintained  in 
DME plus 10% heat-inactivated FBS, 2 mM glutamine, 100 U/ml penicillin, 
and 100 µg/ml streptomycin. HFB4 were seeded at 104 cells/well, in which 
2 ng/ml IL-17A or 20 ng/ml IL-17A/F had been preexposed to serially di-
luted patient sera for 2 h. After incubation at 37°C for 16–20 h, supernatants 
were collected and analyzed for growth-related oncogene  production by 
ELISA (R&D Systems). To assay any remaining IL-17F (10 ng/ml final; pre-
exposed to serially diluted patient sera for 2 h), we additionally preincubated 
NCTC 2544 keratinocytes (Interlab Cell Line Collection) with 0.1 ng/ml 
TNF before the same read-out as with IL-17A neutralization assay (extensive 
checks revealed no antibodies against TNF alone). For IL-22, we instead used 
the cell line Colo205 and measured the IL-10 response. Antibody titers were 
estimated from graphs of ELISA absorbances as the reciprocal serum dilution 
yielding a value halfway between the positive and negative controls.
Statistical analysis. Mann-Whitney or Kruskal-Wallis tests were used to 
compare the median values between groups. Spearman correlation and Fish-
er’s exact test was used to study associations between the variables.
Online supplemental material. Fig. S1 shows additional time points/
cytokine responses of stimulated T cells not shown in Fig. 1. Fig. S2 shows 
IgA autoantibodies against IL-17A, IL-17F, and IL-22 in a set of patients and 
controls,  correlations  between  binding  and  neutralizing  antibodies,  anti-
Th17 cytokine autoantibody levels in four APECED cases sampled before 
onset of CMC, and antibody levels, clinical evolution, and treatments in a 
thymoma patient. Table S1 shows associations between CMC and autoanti-
bodies against Th17 cytokines. Table S2 summarizes clinical evolution and 
autoantibodies  against Th17-related  cytokines  in  thymoma  patients  with 
CMC or episodes of C. albicans infection. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20091669/DC1.
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